Cite
HARVARD Citation
Gandhi, M. et al. (n.d.). EBV+ CNS LYMPHOMAS HAVE A DISTINCTIVE TUMOR MICROENVIRONMENT AND GENETIC PROFILE, WHICH IS AMENABLE TO COMBINATION 3RD PARTY EBV‐SPECIFIC CTL AND IBRUTINIB THERAPY. Hematological oncology. pp. 130-132. [Online].